Arvinas (ARVN) News Today $6.29 +0.05 (+0.80%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.34 +0.05 (+0.81%) As of 08/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Oppenheimer Remains a Hold on Arvinas Holding Company (ARVN)August 9 at 5:10 AM | theglobeandmail.comArvinas Holding Company (ARVN) Gets a Buy from GuggenheimAugust 9 at 5:10 AM | theglobeandmail.comWall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious ApproachAugust 8 at 7:09 PM | msn.comArvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call TranscriptAugust 8 at 7:09 PM | msn.comArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerAugust 8 at 4:05 PM | globenewswire.comHC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock PriceAugust 8 at 12:29 PM | marketbeat.comWells Fargo & Company Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock PriceAugust 8 at 11:51 AM | marketbeat.comGuggenheim Cuts Arvinas (NASDAQ:ARVN) Price Target to $15.00August 8 at 10:34 AM | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Purchased by XTX Topco LtdAugust 7 at 3:38 AM | marketbeat.comArvinas, Inc. (ARVN) Q2 2025 Earnings Call TranscriptAugust 6 at 2:08 PM | seekingalpha.comArvinas Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 6 at 7:00 AM | globenewswire.comFederated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN)August 3, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Price Up 8.6% - Here's WhyJuly 31, 2025 | marketbeat.comInvestors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three yearsJuly 31, 2025 | finance.yahoo.comArvinas to Report Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comMonaco Asset Management SAM Has $2.22 Million Stock Position in Arvinas, Inc. (NASDAQ:ARVN)July 30, 2025 | marketbeat.com10 Promising SmallCap Stocks Under $1 Billion Market CapJuly 24, 2025 | insidermonkey.comArvinas, Inc. (ARVN): A Bull Case TheoryJuly 24, 2025 | msn.comArvinas (ARVN) to Release Earnings on TuesdayJuly 22, 2025 | marketbeat.comArvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma TreatmentJuly 15, 2025 | msn.comArvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 15, 2025 | marketbeat.comArvinas: A Potential 'Sum Of The Parts' StoryJuly 13, 2025 | seekingalpha.comArvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession PlanJuly 9, 2025 | finanznachrichten.deArvinas: John Houston to Retire as President, CEOJuly 9, 2025 | marketwatch.comArvinas (NASDAQ:ARVN) Stock Price Down 4.6% - Should You Sell?July 9, 2025 | marketbeat.comArvinas Announces Retirement of Chief Executive Officer and Succession PlanJuly 9, 2025 | globenewswire.comAndrew Saik Sells 5,700 Shares of Arvinas, Inc. (NASDAQ:ARVN) StockJune 25, 2025 | insidertrades.comInsider Selling: Arvinas, Inc. (NASDAQ:ARVN) CFO Sells 5,700 Shares of StockJune 24, 2025 | marketbeat.comArvinas Sees Unusually High Options Volume (NASDAQ:ARVN)June 20, 2025 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 20, 2025 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Sold by Assenagon Asset Management S.A.June 19, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Shares Gap Up - What's Next?June 17, 2025 | marketbeat.comArvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 CongressJune 13, 2025 | globenewswire.comCantor Fitzgerald Comments on Arvinas FY2026 EarningsJune 11, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNJune 7, 2025 | prnewswire.comArvinas (NASDAQ:ARVN) Stock Price Up 8.7% - Still a Buy?June 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVNJune 6, 2025 | globenewswire.comArvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast CancerJune 6, 2025 | marketwatch.comArvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast CancerJune 6, 2025 | globenewswire.comArvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual MeetingJune 5, 2025 | globenewswire.comWedbush Weighs in on Arvinas' FY2026 Earnings (NASDAQ:ARVN)June 5, 2025 | marketbeat.comLeerink Partnrs Estimates Arvinas' Q2 Earnings (NASDAQ:ARVN)June 4, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Shares Gap Down - Here's WhyJune 3, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Cut to "Hold" at Leerink PartnrsJune 3, 2025 | marketbeat.comLeerink Partners Downgrades Arvinas (ARVN)June 3, 2025 | msn.comArvinas-Pfizer partnership dynamics may shift, says H.C. WainwrightJune 2, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNJune 2, 2025 | globenewswire.comArvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer PatientsJune 2, 2025 | nasdaq.comArvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat PopulationJune 2, 2025 | marketwatch.comArvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink PartnersJune 2, 2025 | marketbeat.com Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Media Mentions By Week ARVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARVN News Sentiment▼0.280.38▲Average Medical News Sentiment ARVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARVN Articles This Week▼167▲ARVN Articles Average Week Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDYA News Today CNTA News Today BHC News Today IBRX News Today AGIO News Today DNLI News Today IRON News Today HRMY News Today CGON News Today MESO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARVN) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
